The Establishment of Biomarkers in Patients with Nocturnal Enuresis: Serum Copeptin and Urinary Aquaporin-2

The Establishment of Biomarkers in Patients with Nocturnal Enuresis: Serum Copeptin and Urinary Aquaporin-2 - Serum Copeptin and Urinary Aquaporin-2 Measurement in Nocturnal Enuresis Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016915

Enrollment

Registered

2015-03-25

Start date

2015-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Monosymptomatic Nocturnal Enuresis

Interventions

Oral desmopressin (Minirin Melt) 120 micrograms or 240 micrograms is given before sleep every day for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with monosymptomatic nocturnal enuresis with more than 4 wet nights per week, without the previous history of desmopressin therapy

Exclusion criteria

Exclusion criteria: Patients with underlying pathologic conditions such as renal, endocrine, metabolic and neurological disorders resulted in nocturnal enuresis

Design outcomes

Primary

Measure	Time frame
Serum Copeptin and urinary Aquaporin-2 levels: before the treatment, 4 and 8 weeks after the treatment, and after the treatment	—

Secondary

Measure	Time frame
Urine volume during the night, urinary osmolarity and creatinine before and after sleep : before the treatment, 4 and 8 weeks after the treatment, and after the treatment	—

Countries

Japan

Contacts

Public ContactMiyuki Katsuki

Juntendo University Nerima Hospital GCP Center

gcp@juntendo-nerima.jp+81-3-59233111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026